586 related articles for article (PubMed ID: 19769082)
1. [Integrase inhibition].
Bogner JR
MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
[No Abstract] [Full Text] [Related]
2. [Integrase inhibition--a new mode of action in HIV therapy].
van Lunzen J; Degen O
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
[No Abstract] [Full Text] [Related]
3. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
5. [Integrase inhibitor: raltegravir also as first line therapy].
MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
[No Abstract] [Full Text] [Related]
6. Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
[No Abstract] [Full Text] [Related]
7. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
8. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
9. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
Murphy RL
AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
[TBL] [Abstract][Full Text] [Related]
10. Initial results reported on raltegravir once-daily dosing.
AIDS Patient Care STDS; 2011 Feb; 25(2):123. PubMed ID: 21370546
[No Abstract] [Full Text] [Related]
11. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
Cabrera C
Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
[TBL] [Abstract][Full Text] [Related]
12. [Resistance screening].
Sierra S; Lengauer T; Kaiser R
MMW Fortschr Med; 2009 Apr; 151(18):72, 74-5. PubMed ID: 19769083
[No Abstract] [Full Text] [Related]
13. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
14. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
[No Abstract] [Full Text] [Related]
15. [Raltegravir as first integrase inhibitor in an HIV-infection].
Papendorp SG; Brinkman K
Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
[No Abstract] [Full Text] [Related]
16. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
17. Isentress gets another good grade.
Dalton P
Proj Inf Perspect; 2008 Sep; (46):9. PubMed ID: 19043877
[No Abstract] [Full Text] [Related]
18. HIV integrase inhibitors--out of the pipeline and into the clinic.
Havlir DV
N Engl J Med; 2008 Jul; 359(4):416-8. PubMed ID: 18650518
[No Abstract] [Full Text] [Related]
19. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
20. Trial will evaluate a once-daily dose of raltegravir.
AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
[No Abstract] [Full Text] [Related]
[Next] [New Search]
